Biochemical Insights into Imipenem Collateral Susceptibility Driven by <i>ampC</i> Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa

Published:2023-02-16 Issue:2 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cabot Gabriel¹^ORCID,Kim Kihun²^ORCID,Mark Brian L.²^ORCID,Oliver Antonio¹^ORCID,Khajehpour Mazdak³^ORCID

Affiliation:

1. Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain

2. Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

3. Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada

Abstract

Several Pseudomonas aeruginosa AmpC mutants have emerged that exhibit enhanced activity against ceftazidime and ceftolozane, while also evading inhibition by avibactam. Interestingly, P. aeruginosa strains harboring these AmpC mutations fortuitously exhibit enhanced carbapenem susceptibility.

Funder

Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01409-22

Reference23 articles.

1. Pseudomonas Aeruginosa: Resistance to the Max

2. How Bacteria Consume Their Own Exoskeletons (Turnover and Recycling of Cell Wall Peptidoglycan)

3. β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein